Search research articles
Contact Us
Filters
Showing results (561-570 of 570) with videos related to
Page
of 57
Sort By:
You have reached the last page of results.
This site can display upto 570 results.
Neurology
|
May 30, 2008
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study
J E Tobin, J C Latourelle, M F Lew, et al.
Nature Genetics
|
July 28, 2014
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
Mike A Nalls, Nathan Pankratz, Christina M Lill, et al.
Annals of Clinical and Translational Neurology
|
June 19, 2025
Genetic Diversity and Expanded Phenotypes in Dystonia: Insights From Large-Scale Exome Sequencing
Mirja Thomsen, Fabian Ott, Sebastian Loens, et al.
BMC Medicine
|
November 7, 2008
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
Jeanne C Latourelle, Mei Sun, Mark F Lew, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 28, 2021
A Multi-center Genome-wide Association Study of Cervical Dystonia
Yan V Sun, Chengchen Li, Qin Hui, et al.
Neurology
|
December 4, 2016
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Andrew McGarry, Michael McDermott, Karl Kieburtz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 17, 2024
Genetic Risk Factors in Isolated Dystonia Escape Genome-Wide Association Studies
Björn-Hergen Laabs, Katja Lohmann, Eva-Juliane Vollstedt, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
JAMA Neurology
|
November 17, 2015
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials
, Kevin Michael Biglan, Ira Shoulson, et al.
JAMA Neurology
|
March 26, 2014
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit
, M Flint Beal, David Oakes, et al.
Page
of 57
Search research articles
Search
Showing results (561-570 of 570) with videos related to
Sort By:
Page
of 57
You have reached the last page of results.
This site can display upto 570 results.
Neurology
|
May 30, 2008
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study
J E Tobin, J C Latourelle, M F Lew, et al.
Nature Genetics
|
July 28, 2014
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
Mike A Nalls, Nathan Pankratz, Christina M Lill, et al.
Annals of Clinical and Translational Neurology
|
June 19, 2025
Genetic Diversity and Expanded Phenotypes in Dystonia: Insights From Large-Scale Exome Sequencing
Mirja Thomsen, Fabian Ott, Sebastian Loens, et al.
BMC Medicine
|
November 7, 2008
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
Jeanne C Latourelle, Mei Sun, Mark F Lew, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 28, 2021
A Multi-center Genome-wide Association Study of Cervical Dystonia
Yan V Sun, Chengchen Li, Qin Hui, et al.
Neurology
|
December 4, 2016
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Andrew McGarry, Michael McDermott, Karl Kieburtz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 17, 2024
Genetic Risk Factors in Isolated Dystonia Escape Genome-Wide Association Studies
Björn-Hergen Laabs, Katja Lohmann, Eva-Juliane Vollstedt, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
JAMA Neurology
|
November 17, 2015
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials
, Kevin Michael Biglan, Ira Shoulson, et al.
JAMA Neurology
|
March 26, 2014
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit
, M Flint Beal, David Oakes, et al.
Page
of 57